{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T20:53:02Z","timestamp":1694638382560},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.disamonth.2009.12.010","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T13:27:45Z","timestamp":1269955665000},"page":"215-232","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets"],"prefix":"10.1016","volume":"56","author":[{"given":"Albert","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Paparello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2 Suppl 1","key":"10.1016\/j.disamonth.2009.12.010_bib1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJM198312223092503","article-title":"Use of single voided urine samples to estimate quantitative proteinuria","volume":"309","author":"Ginsberg","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies: \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia'' (GISEN)","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2009.12.010_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end-stage renal disease","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2009.12.010_bib5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.disamonth.2009.12.010_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0272-6386(03)00742-X","article-title":"Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study","volume":"42","author":"Romundstad","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0002-8703(84)90763-4","article-title":"The prognostic significance of proteinuria: the Framingham study","volume":"108","author":"Kannel","year":"1984","journal-title":"Am Heart J"},{"issue":"4 Suppl 1","key":"10.1016\/j.disamonth.2009.12.010_bib8","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0272-6386(00)70237-X","article-title":"Proteinuria: its clinical importance and role in progressive renal disease","volume":"35","author":"Keane","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1046\/j.1523-1755.2001.0590041211.x","article-title":"Renoprotection: one or many therapies?","volume":"59","author":"Hebert","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2009.12.010_bib10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.ASN.0000018401.82863.FD","article-title":"Smoking and the kidney","volume":"13","author":"Orth","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.disamonth.2009.12.010_bib11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.disamonth.2009.12.010_bib12","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.disamonth.2009.12.010_bib13","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2009.12.010_bib14","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2009.12.010_bib16","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2009.12.010_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2009.12.010_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib23","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/S0272-6386(01)70008-X","article-title":"K\/doqi clinical practice guidelines for anemia of chronic kidney disease","volume":"37","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/ajkd.2001.27699","article-title":"Anemia: an early complication of chronic renal insufficiency","volume":"38","author":"Kazmi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib25","first-page":"S98","article-title":"The long-term effects of recombinant human erythropoietin on the cardiovascular system","volume":"38","author":"Eschbach","year":"1992","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.disamonth.2009.12.010_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0272-6386(97)90335-8","article-title":"Cardiovascular effects of recombinant human erythropoietin in predialysis patients","volume":"29","author":"Portoles","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib27","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ki.1996.201","article-title":"Outcome and risk factors of ischemic heart disease in chronic uremia","volume":"49","author":"Parfrey","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2009.12.010_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ki.1991.20","article-title":"rHuEPO treatment improves brain and cognitive function of anemic dialysis patients","volume":"39","author":"Marsh","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2009.12.010_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.ajkd.2005.05.018","article-title":"Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes","volume":"46","author":"Collins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib31","doi-asserted-by":"crossref","first-page":"s39","DOI":"10.1053\/ajkd.2000.19930","article-title":"Anemia management in patients with chronic renal insufficiency","volume":"36","author":"Kausz","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00041552-199503000-00008","article-title":"The use of recombinant human erythropoietin in pre-dialysis patients","volume":"4","author":"Besarab","year":"1995","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.disamonth.2009.12.010_bib33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1053\/ajkd.2001.29264","article-title":"Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease","volume":"38","author":"Nissenson","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib34","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.disamonth.2009.12.010_bib35","first-page":"A258","article-title":"Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia","volume":"9","author":"Macdougall","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.disamonth.2009.12.010_bib36","first-page":"S11","article-title":"K\/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib38","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2009.12.010_bib39","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"issue":"4 Suppl 3","key":"10.1016\/j.disamonth.2009.12.010_bib40","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.disamonth.2009.12.010_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation Between Kidney Function, Proteinuria, and Adverse Outcomes","volume":"303","author":"Hemmelgrem","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2009.12.010_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal Outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.disamonth.2009.12.010_bib43","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0140-6736(09)61768-2","article-title":"Retraction\u2014Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial","volume":"374","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.disamonth.2009.12.010_bib44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of Darbopoietin Alpha in Type 2 Diabetes and Chronic Kidney Disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.disamonth.2009.12.010_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMp0912328","article-title":"Erythropoiesis-Stimulating Agents \u2013 Time for a Revealuation","volume":"362","author":"Unger","year":"2010","journal-title":"NEJM"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502909001588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502909001588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T05:31:33Z","timestamp":1635139893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502909001588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0011502909001588"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2009.12.010","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}